Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women

References

• Melton 14 3rd, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005–10
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992;117: 1016–37
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333–40
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, etal. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with ralcodfene: results from a 3-year randomized clinical trial. Multiple Outcomes of Ralcodfene Evaluation (MORE) Investigators. J Am Med Assoc 1999;282:637–45
   Google Scholar
• Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteo-porosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000;109: 267–76
   Google Scholar
• Wells G, Tugwell P, Shea B, et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529–39
   Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321–33
   Google Scholar
• Saitta A, Morabito N, Frisina N, et al. Cardiovascular effects of ralcodfene hydrochloride. Cardiovasc Drug Rev 2001;19:57–74
   PubMed Web of Science ®Google Scholar
• Qu Q, Zheng H, Dahllund J, etal. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and repro-ductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809–20
   PubMed Web of Science ®Google Scholar
• Qu Q, Härkonen PL, Väändnen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999;73:500–7
   PubMed Web of Science ®Google Scholar
• Parikka V, Lehenkari PP, Härkönen PL, et al. The effect of two selective estrogens ralcodfene and FC1271a on osteoclast survival and resorption in vitro. J Bone Miner Res 1998;23: 5552
   Google Scholar
• Voipio SK, Komi J, Kangas L, et al. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43: 207–14
   PubMed Web of Science ®Google Scholar
• Rutanen E-M, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and on quality of life in postmenopausal women: a double-blind randomized trial. Menopause 2003;10:433–9
   Google Scholar
• Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteo-porosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11:S2–17
   PubMedGoogle Scholar
• Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11:566–76
   Google Scholar
• Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy postmenopausal women. Menopause 2003;10:440–7
   PubMed Web of Science ®Google Scholar
• Simberg N, Tiitinen A, Silfvast A, et al. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen—progestin replacement. J Clin Endocrinol Metab 1996;81:646–51
   PubMedGoogle Scholar
• Marttunen MB, Hietanen P, Tiitinen A, et al. Com-parison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in post-menopausal breast cancer patients. J Clin Endocrinol Metab 1998;83:1158–62
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79:1693–700
   PubMed Web of Science ®Google Scholar
• Chesnut CH 3rd, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102: 29–37
   Google Scholar
• Peacock M, Liu G, Carey M, etal. Effect of calcium or 250H vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000;85:3011–19
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of ralcodfene on bone mineral density, serum choles-terol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641–7
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteo-porosis with ralcodfene: a randomized trial. J Bone Miner Res 1998;13:1747–54
   PubMed Web of Science ®Google Scholar